Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03059472 · ClinicalTrials.gov registry record · NA

Strong Hearts for New York: A Rural Heart Disease Prevention Study

A NA study, sponsored by Cornell University.

Completed
Registry status
NA
Development phase
182
Enrollment target

NCT03059472: Completed NA study, sponsored by Cornell University.

NCT03059472 is a NA study that has completed, run by Cornell University. The registered enrollment target is 182 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (87% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03059472, a NA study, has completed, sponsored by Cornell University.

COMPLETED
Registry status
NA
Development phase
182 participants
Enrollment target

Study Summary

Strong Hearts for New York is a research study which aims to reduce cardiovascular disease (CVD), improve quality of life, and reduce CVD related health care costs in rural communities. Our aim is to better understand how changes in lifestyle can affect the health of rural women and others in their communities.

Interventions

  • BEHAVIORAL Group 1 (Intervention)
  • BEHAVIORAL Group 2 (Delayed intervention)

Trial Details

FieldValue
Enrollment Target 182 participants
Start Date 2017-03-31
Est. Completion 2019-02-28
Phase NA
Cornell University

66 total trials

What the finished NCT03059472 record still lists

NCT03059472 is an interventional study that assigns participants to a tested intervention. The registered 182 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (87% lower).

The record links to 0 conditions, and to 2 interventions - of which Group 1 (Intervention) is the first listed.

NCT03059472 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT03059472 about?

NCT03059472 is a clinical study titled "Strong Hearts for New York: A Rural Heart Disease Prevention Study". Strong Hearts for New York is a research study which aims to reduce cardiovascular disease (CVD), improve quality of life, and reduce CVD related health care costs in rural communities. Our aim is to better understand how changes in lifestyle can affect the health of rural women and others in their ...

What is the current status of trial NCT03059472?

This trial is currently completed. It is a NA study. The enrollment target is 182 participants. The study started on 2017-03-31. Estimated completion is 2019-02-28.

What interventions are being tested in trial NCT03059472?

The interventions under investigation include: Group 1 (Intervention) (BEHAVIORAL), Group 2 (Delayed intervention) (BEHAVIORAL).

Who is sponsoring clinical trial NCT03059472?

This trial is sponsored by Cornell University, which has 66 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT03059472's enrollment target sits among peer trials

182 584th of 2000 higher than 1,415 of 2,000 other NA trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT03897998 · 182 participants · Phase 2

    Neural Correlates of Hypoalgesia Driven by Observation

  • NCT04300556 · 182 participants · Phase 1

    A Study to Evaluate the Safety, Tolerability, and Efficacy of MORAb-202 (Herein Referred to as Farletuzumab Ecteribulin), a Folate Receptor Alpha (FRα)-Targeting Antibody-drug Conjugate (ADC) in Participants With Selected Tumor Types

  • NCT04323735 · 182 participants · Phase 2

    Intravesical Lactobacillus for Urinary Symptoms Among People With NLUTD Who Use Indwelling Catheters

  • NCT05606731 · 182 participants · NA

    Family Intervention to Prevent Childhood Obesity

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT03059472, the US trial registry maintained by the National Library of Medicine. NCT03059472 (mid enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.